MHLW accepts GSK’s multiple myeloma treatment NDA for review
Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK's new drug application (NDA) for Blenrep ...
Pharmabiz3d
Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma
Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...
GSK: Japan Accepts For Review NDA For Blenrep Combinations In Relapsed/refractory Multiple Myeloma
Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...
Here's Why Investors Should Invest in Arcturus Stock Now
In the past 60 days, the Zacks Consensus Estimate for Arcturus’ 2024 loss per share has narrowed from $4.39 to $2.60. Also, the Zacks Consensus Estimate for 2025 has moved from a loss of 45 cents to ...
Pharmabiz5d
Japan’s MHLW approves CSL & Arcturus’ updated sa-mRNA Covid-19 vaccine for protection against JN.1 strain
King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...